CD8A and glioma: ML-driven classification of gliomas from large databases into distinct immune subtypes (e.g., IM1-IM4; IMA-IMD) additionally segregates those in richer natural killer (NK) and CD8+ T-cell settings, amplified leucocyte activation and cytotoxicity, etc., to identify patients with favourable genetic mutation profiles and subsequently longer overall survival following immunotherapy [157].